sr141716 has been researched along with u 0126 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dragunow, M; Glass, M; Goodfellow, CE; Graham, ES; Scotter, EL | 1 |
| Dang, DK; Jang, CG; Jeong, JH; Kim, HC; Ledent, C; Mai, AT; Nabeshima, T; Nah, SY; Onaivi, ES; Shin, EJ; Yamamoto, T | 1 |
2 other study(ies) available for sr141716 and u 0126
| Article | Year |
|---|---|
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
Topics: Animals; Butadienes; Cell Culture Techniques; Cell Death; Cell Line, Transformed; Cerebellum; Cyclic AMP; Dronabinol; GTP-Binding Protein alpha Subunits; Humans; Huntingtin Protein; Huntington Disease; Mice; Mitogen-Activated Protein Kinase 3; Nerve Tissue Proteins; Neuroprotective Agents; Nitriles; Nuclear Proteins; PC12 Cells; Pertussis Toxin; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Receptors, Dopamine; Rimonabant | 2010 |
Genetic or pharmacological depletion of cannabinoid CB1 receptor protects against dopaminergic neurotoxicity induced by methamphetamine in mice.
Topics: Animals; Apoptosis; Butadienes; Cells, Cultured; Corpus Striatum; Dopamine; Extracellular Signal-Regulated MAP Kinases; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurotoxicity Syndromes; Nitriles; Oxidative Stress; Piperidines; Protein Kinase C-delta; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, Dopamine D2; Rimonabant; Sulpiride | 2017 |